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Abstract
Background: This study was carried out at Punjab Institute of Mental Health and Centre for Nuclear Medicine Mayo Hospital, Lahore. It is aimed at the possible 
association of thyroid malfunctioning with suicide attempts of patients. Objective: Determination of thyroid function status of suicidal psychiatric patients 
and their comparison with psychiatric patients without suicide attempt or ideation. Methods: Total 54 patients with either past history of suicide attempt or 
current suicidal ideation were selected for analysis of their thyroid function status (age 15-55 years). Age matched 50 non-suicide psychiatric patients were 
included for comparison. Results: Two patients with suicide attempt had overt thyroid dysfunction. Remaining patients had serum FT4, FT3 and TSH level 
within normal range. Suicide attempter patients had lower FT4 but increased FT3 and TSH levels compared to suicidal ideation patients. Serum FT4 and TSH 
levels in suicidal patients were not different from psychiatric patients. Serum FT3 in suicidal patients was lower than psychiatric patients (3.7 ± 0.8 vs. 4.3 ± 
0.5; p < 0.05). Female suicidal patients had lower FT3 levels compared to male patients (3.4 ± 0.6 vs. 3.9 ± 0.8 pmol/L; p < 0.05). Discussion: Local suicidal 
patients have higher incidence of overt thyroid disorder and lower FT3 levels compared to non-suicidal psychiatric patients.  
Khurshid S et al. / Arch Clin Psychiatry. 2018;45(1):12-4
Keywords: Suicide, thyroid hormone, psychiatric patients, depression.
Address for correspondence: Muhammad Pervaiz. E-mail: mpbhatti786@gmail.com / Syed Majid Bukhari. E-mail: majidbukhari@ciit.net.pk.
Introduction
Death is a bitter reality of human life everyone is scared of. Mentally 
healthy persons never want to die. Still, there are present such 
individuals in our society who really want to leave this world by 
committing suicide. Such individuals are considered as mentally 
unhealthy and require immediate medical treatment. Suicide is a 
complex issue which involves a number of social, cultural, biological 
as well as psychological factors. In the last 45 years, the world has 
seen 60% increase in the suicide attempts with a prediction that 
global suicide figures will potentially reach to 1.5 million mark by 
the year 20201,2. This shocking act of uncivilized behavior is now 
attributed to the presence of a psychiatric disorder. This disorder is 
among the most consistently reported risk factors associated with 
the suicidal attempts. It is now known that more than 90% of people 
who either attempt a suicide or die as a result of attempting suicide 
are psychiatrically ill3. This fact is further supported by the recent 
studies which proves that the depressed individuals attempting 
suicide constitute a particular subgroup of depressed subjects with a 
higher severity of depressive disorder and higher social impairment4. 
This psychiatric illness may arise as a result of abnormalities 
originating within the human body, particularly hormonal 
disturbances. The thyroid hormones are known to have profound 
effects on mood swings as well as human behavior. In the recent 
attempts to investigate the relationship between suicidal behavior 
and thyroid hormonal activity in depressed patients, it was reported 
that various degrees of hypothalamic-pituitary-thyroid (HPT) axis 
dysregulation are associated with the history of suicide5,6. 
The activity of thyroid is considerably regulated by iodine 
and, unfortunately, Pakistan is considered one of the severely 
iodine deficient countries in the region7.  About 70% of Pakistani 
population is reported to be at risk of iodine deficiency disorder8. 
In this context, it is expected that a number of psychiatric patients 
may have underlying thyroid abnormalities which can lead towards 
suicide attempts. So far, the data from Pakistan, on prevalence of 
abnormal thyroid hormones among psychiatric patients, has not 
been reported9,10. Therefore, present study is a part of a large study 
exploring the role of thyroid hormone in psychiatric patients. The 
current study focuses on determination of serum levels of free 
thyroxin (FT4), free triidothyronine (FT3) and thyroid stimulating 
hormone (TSH) in the patients who undergo suicide attempts (SA) 
as well as suicide ideation (SI) and the obtained results are compared 
with psychiatric patients without suicide attempts or ideation. 
Material and methods
The details of patients for this study and the methods adopted has 
been provided.
Patients
Consecutive patients with past history of SA or SI were recruited from 
outpatient department of Institute of Mental Health, Lahore during 
June to September 2013. A careful Psychiatric history of each patient 
was taken and noted on a proforma by the qualified psychiatrist. For 
each patient, the physical examination of thyroid gland as well as 
signs and symptoms associated with thyroid dysfunction were also 
carried out. The patients already diagnosed with thyroid diseases 
and were either taking thyroid medications or underwent a thyroid 
surgery, the pregnant women and patients suffering from cardiac 
diseases and hepatitis were excluded from this study.
Methods 
A 5.0 mL blood sample was taken from each patient in the study. The 
serum was separated from each sample by low-speed centrifugation 
(2000×g) for 5 minutes at room temperature and stored at minus 
20 °C until analysis. All collected serum samples were analyzed for 
FT4, FT3 and TSH at CENUM, Mayo Hospital, Lahore. The serum 
FT4 and FT3 were determined by radioimmunoassay (RIA) and 
TSH was determined by IRMA techniques using commercial kits 
of Immunotech Inc. (Beckman, Czech Republic). The RIA & IRMA 
batches were tested with commercially derived control sera at low, 
medium and high concentrations. Measurement of radioactivity, 
fitting of the standard curve and analysis of samples was carried out 
using a computerized gamma counter (Cap-RIA 16, Capintec Inc. 
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USA). Assay reliability was determined by the use of commercially 
derived control sera of low, medium and high concentrations which 
were included in every test. All assays were carried out in duplicate. 
The RIA and IRMA results were expressed at less than 10% CV 
of imprecision profile. Normal ranges for FT4, FT3 and TSH, as 
standardized in CENUM RIA laboratory, are 11.0-22.0 pmol/L, 
2.5-5.8 pmol/L and 0.3-5.0 mIU/L, respectively. The diagnosis of 
hyperthyroidism was marked as positive if serum TSH was found to 
be < 0.3 mIU/L and FT4 > 22 pmol/L. Hypothyroidism was considered 
if serum TSH was > 5.0 mIU/L and FT4 < 11.0 pmol/L.
The analysis of data was carried out using Microsoft Excel 
program on a personal computer. Mean values were compared by 
Student t-test in order to test the significance of difference between 
two arbitrary groups. A value of p < 0.05 was considered as significant.
Results 
A total number of 54 consecutive psychiatric patients (21 females and 
33 males) presenting with SA (n = 39) or SI (n = 15) were selected 
for this study. Their mean (± SD) age was 30.5 ± 10.1 years with age 
ranging from 15 to 55 years. Among them 24 (44.4%) were residents 
of Lahore city. As controls, age matched 50 patients (22 females and 
28 males) with psychiatric disorder but no history of either past 
suicide attempts or current suicidal ideation were included in this 
study. Analysis of thyroid function tests showed that among 39 SA 
patients, one female and one male had severe hypothyroidism and 
hyperthyroidism, respectively (prevalence: 5.1%). The remaining 52 
patients were found to have serum FT4, FT3 and TSH levels within the 
normal range. Among them a comparison of mean concentration of 
serum FT4, FT3 and TSH levels between SA and SI patients is shown in 
Table 1. The SA patients were found to have lower FT4 and increased 
FT3 and TSH levels as compared to those of SI patients. However, 
difference was slight and did not reach significant level. Thus, thyroid 
function tests were not different in patients who have attempted 
suicide compared to those who have current suicidal ideation.
Discussion
The aim of this study was to determine thyroid function status of 
suicidal psychiatric patients and their comparison with those of 
non-suicidal psychiatric patients. The results of this study showed 
that the thyroid function tests were not significantly different 
among suicidal patients who had either attempted suicide in 
the past or were currently idealizing it. Compared to psychiatric 
patients without suicide history or idealization, suicidal patients had 
significantly decreased serum FT3 levels. This decrease in FT3 levels 
was comparatively more pronounced in female suicidal patients as 
compared to male suicidal patients. A noteworthy result was that 
more than 5.0% patients with past history of suicide attempt had 
severe thyroid dysfunction. This points towards the speculation that 
before a patient attempts suicide, his or her thyroid hormones may 
get dis regulated6. 
Mann and Currier have reviewed the prospective studies of 
suicidal behavior and serotonergic, noradrenergic, dopaminergic 
and hypothalamic-pituitary adrenocortical (HPA) as well as HPT 
axis in mood disorders11. The relationship between suicide and the 
HPT activity has been previously described in the literature6,12-15. 
Most of these studies have focused on the change in serum TSH 
levels among the suicidal patients as compared to the depressive 
patients. These studies report conflicting results regarding serum 
TSH. Although most of the investigators have found that depressed 
patients with either a suicidal behavior or intent exhibited a 
reduced TSH response to morning administration of thyrotropin 
releasing hormone (TRH)6,12,13 while others did not agree to this 
generalization13,14. In these reports, the serum FT4 and FT3 levels 
were not studied extensively in suicidal patients due to preoccupation 
with serum TSH. Recently, Duval et al.6 carried out a study on 95 
medication-free DSM-IV euthyroid major depressed inpatients 
along with 44 healthy hospitalized controls; they found that control 
patients with a positive suicide history (n = 53) showed lower basal 
FT4 (at 0800 h: p < 0.005; at 2300 h: p < 0.03) and normal FT3 levels, 
whereas patients with a negative suicide history (n = 42) showed 
normal FT4 and FT3 levels6. In contrast to this finding, Pompili 
conducted a study on 439 patients suffering from major depression 
disorder, bipolar disorder and psychotic disorders (schizophrenia, 
schizoaffective disorder and psychosis not otherwise specified). They 
found that suicide attempters and non-attempters differ regarding 
their FT3 values only. A multinomial logistic regression model 
revealed that suicidal attempters were 2.27 times (odds ratio = 0.44; 
95% confidence interval: 0.23/0.82; p = 0.01) less likely to have higher 
FT3 values than non-attempters. Earlier Jokinen et al. have shown that 
suicide patients’ plasma T3 had a negative correlation with the Beck 
Suicide Intent Scale and the Montgomery Asberg Depression rating 
scale16. Thus, these few studies on FT4 and FT3 are not consistent 
regarding serum FT4 and FT3 levels in suicidal patients. The results 
of this study are in accordance to Pompili showing that serum FT3 
levels were significantly lower in suicidal patients as compared to 
non-suicidal patients. 
Disturbances in the serotonin (5-hydroxytryptamine, 5-HT) 
system constitute the most common biochemical abnormality 







FT4 (pmol/L) 14.8 ± 3.2 16.0 ± 3.2 0.79
FT3 (pmol/L) 3.7 ± 0.8 3.6 ± 0.6 0.38
TSH (IU/L) 2.3 ± 1.0 1.7 ± 0.9 0.66
All control patients also had normal levels of thyroid related 
hormones. A comparison of mean concentration of serum FT4, FT3 
and TSH in suicidal and control patients is shown in Table 2. Results 
showed that mean FT4 and TSH levels in suicidal patients were not 
different from psychiatric patients. However, serum FT3 in suicidal 
patients was significantly lower than psychiatric patients. 







FT4 (pmol/L) 15.1 ± 3.2 15.0 ± 2.2
0.335FT3 (pmol/L) 3.7 ± 0.8 4.3 ± 0.5
TSH (IU/L) 2.1 ± 1.0 2.3 ± 1.1
We further explored the effect of different patient’s variables on 
serum FT3 levels in suicidal patients; results are shown in Table 3. 
In female suicidal patients, the FT3 levels were significantly reduced 
as compared to the male patients. However, patient’s education 
level as well as place of residence has no effect on serum FT3 levels 
in suicidal patients.
Table 3. Effect of different variables on mean serum FT3 levels in suicidal 
patients
Variable FT3 levels (pmol/L) P-value
Gender
Male 3.9 ± 0.8 0.01
Female 3.4 ± 0.6
Educational level
Matriculation and above 3.8 ± 0.7 0.69
Below matriculation 3.7 ± 0.8
Place of residence
Inside Lahore 3.5 ± 0.6 0.15
Outside Lahore 4.2 ± 0.9
14 Khurshid S et al. / Arch Clin Psychiatry. 2018;45(1):12-4
associated with suicide17. It is proposed that thyroid hormones are 
involved in a complex compensatory mechanism to correct reduced 
central 5-HT activity with existence of either of the two situations12. 
The compensatory mechanisms are effective: in this situation decrease 
in 5-HT function leads to an increase in thyroid axis activity. This 
may be understood as a repairing process aiming to restore an 
efficient 5-HT functioning and the compensatory mechanisms are 
not effective: in this case the 5-HT deficiency remains. In depressed 
patients with a history of suicidal behavior, 5-HT dysfunction may be 
understood as a failure of the compensatory mechanisms. If thyroid 
hormones might be involved in a complex compensatory mechanism 
to correct reduced central serotonin activity, then the lower FT3 levels 
in our patients mean the failure of thyroid compensation of serotonin 
secretion. In the past studies regarding TSH, the TRH hyper secretion 
has been considered a compensatory mechanism to maintain normal 
thyroid hormone secretion and to normalize serotonin activity in 
depressed patients12,13.
The strength of the present study is the enrollment of consecutive 
suicidal patients constituting a measure of homogeneousness. 
Similarly, control group of patients was suffering from psychiatric 
disorders which made it suitable for differentiation between the 
effect of the psychiatric illness and the effect of suicidal behavior. 
However, there are some limitations to the generalization of the 
present results. First, the relatively small sample size may affect the 
replicability of results. Second, the sample of patients taken was not 
free of medication which might have affected thyroid hormone values.
Further, large studies should confirm this generated data 
regarding higher prevalence of overt thyroid diseases and lower FT3 
levels in local suicidal patients. Moreover, studies should be conducted 
to ascertain whether thyroid hormonal patterns found in suicide 
attempts can be ameliorated with T3 supplementation before starting 
anti-depressive treatment. In the past, most of such acceleration 
studies have yielded favorable results before the use of tricyclic 
antidepressants18. Recently, it has been suggested that hyperactive 
HPT axis is associated with better antidepressant response and T3 due 
to its short half-life may reduce the antidepressant response time19. 
This necessitates the trial of T3 as acceleration agent before start of 
selective serotonin reuptake inhibitors (SSRIs). Such studies are of 
great importance because use of SSRIs alone have not completely 
eliminated the risk of future suicide attempt in admitted depressive 
patients20, particularly the bipolar disorder patients21. 
Conclusion
It has been observed from the present study that suicide attempting 
patients do not differ significantly in the levels of their FT4, FT3 and 
TSH when compared to those with suicidal ideation. Also, Serum FT4 
and TSH levels in suicidal and psychiatric patients were almost the 
same. However, serum FT3 in suicidal patients was significantly lower 
than psychiatric patients as far as females are concerned. Female 
suicidal patients had lower FT3 levels compared to male patients. It 
has also been noted that local suicidal patients have higher incidence 
of overt thyroid disorder as well as significantly lower FT3 levels as 
compared to non-suicidal psychiatric patients.
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